AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Boundless Bio Q2 R&D Expenses Down 17%, Cash to Fund Operations Until H1 2028
ByAinvest
Tuesday, Aug 5, 2025 9:13 pm ET1min read
Boundless Bio (BOLD) reported Q2 R&D expenses of $12.2mln, a 17% drop from the same period in 2024. Cash and investments totaled $127.1mln, expected to fund operations into H1 2028. The biotech company develops targeted cancer therapies based on extrachromosomal DNA biology.
Boundless Bio (NASDAQ: BOLD), a biotechnology company focused on developing targeted cancer therapies based on extrachromosomal DNA (ecDNA) biology, released its second-quarter 2025 financial results. The company reported a significant reduction in research and development (R&D) expenses, with costs dropping to $12.2 million, a 17% decrease from the same period in 2024 [1].The quarter ended with $127.1 million in cash, cash equivalents, and short-term investments, which management expects to fund operations into the first half of 2028 [1]. This financial position supports the company's ongoing clinical trials and pipeline development.
Boundless Bio's core focus is its Spyglass platform, which identifies drug targets involved in ecDNA function. The company's lead program, BBI-355, targets oncogene amplification through small molecule drugs. Additionally, the company is developing BBI-940, a new oncology drug targeting kinesin, a protein that plays a role in cell division [1].
The company's second-quarter 2025 financial results also include a net loss of $15.7 million, compared to $17.0 million in the same period in 2024. General and administrative expenses were $4.8 million, up slightly from $4.7 million in the same period in 2024 [1].
Looking ahead, investors should monitor progress in the BBI-355/BBI-825 combination trial and the regulatory submission timeline for BBI-940. Success in these programs will drive future updates and may influence funding needs if clinical milestones shift. The company will remain pre-revenue until its drug candidates advance further in clinical development and eventually gain regulatory approval [1].
References:
[1] https://www.nasdaq.com/articles/boundless-bio-bold-q2-rd-drops-17
[2] https://www.morningstar.com/news/globe-newswire/9506127/boundless-bio-reports-second-quarter-2025-financial-results-and-business-highlights
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet